189 related articles for article (PubMed ID: 20881950)
1. Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan.
Abduljalil K; Frank D; Gaedigk A; Klaassen T; Tomalik-Scharte D; Jetter A; Jaehde U; Kirchheiner J; Fuhr U
Clin Pharmacol Ther; 2010 Nov; 88(5):643-51. PubMed ID: 20881950
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and polymorphic oxidation of dextromethorphan in a Japanese population.
Nagai N; Kawakubo T; Kaneko F; Ishii M; Shinohara R; Saito Y; Shimamura H; Ohnishi A; Ogata H
Biopharm Drug Dispos; 1996 Jul; 17(5):421-33. PubMed ID: 8830977
[TBL] [Abstract][Full Text] [Related]
3. Effects of the Chinese herbal formula "Zuojin Pill" on the pharmacokinetics of dextromethorphan in healthy Chinese volunteers with CYP2D6*10 genotype.
Qiu F; Liu S; Miao P; Zeng J; Zhu L; Zhao T; Ye Y; Jiang J
Eur J Clin Pharmacol; 2016 Jun; 72(6):689-95. PubMed ID: 27023460
[TBL] [Abstract][Full Text] [Related]
4. CYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population.
Dorado P; Heras N; Machín E; Hernández F; Teran E; Llerena A
Eur J Clin Pharmacol; 2012 May; 68(5):637-44. PubMed ID: 22083166
[TBL] [Abstract][Full Text] [Related]
5. In-vivo indices of CYP2D6 activity: comparison of dextromethorphan metabolic ratios in 4-h urine and 3-h plasma.
Chládek J; Zimová G; Beránek M; Martínková J
Eur J Clin Pharmacol; 2000 Dec; 56(9-10):651-7. PubMed ID: 11214771
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groups.
Britzi M; Bialer M; Arcavi L; Shachbari A; Kapitulnik T; Soback S
Ther Drug Monit; 2000 Oct; 22(5):510-6. PubMed ID: 11034254
[TBL] [Abstract][Full Text] [Related]
7. Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphism on pharmacokinetics and pharmacodynamics: dextromethorphan as a model application.
Dickinson GL; Rezaee S; Proctor NJ; Lennard MS; Tucker GT; Rostami-Hodjegan A
J Clin Pharmacol; 2007 Feb; 47(2):175-86. PubMed ID: 17244768
[TBL] [Abstract][Full Text] [Related]
8. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C
Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
[TBL] [Abstract][Full Text] [Related]
9. Application of a physiologically based pharmacokinetic model for the evaluation of single-point plasma phenotyping method of CYP2D6.
Chen R; Rostami-Hodjegan A; Wang H; Berk D; Shi J; Hu P
Eur J Pharm Sci; 2016 Sep; 92():131-6. PubMed ID: 27412587
[TBL] [Abstract][Full Text] [Related]
10. Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination.
Tennezé L; Verstuyft C; Becquemont L; Poirier JM; Wilkinson GR; Funck-Brentano C
Clin Pharmacol Ther; 1999 Dec; 66(6):582-8. PubMed ID: 10613613
[TBL] [Abstract][Full Text] [Related]
11. Alternative methods for CYP2D6 phenotyping: comparison of dextromethorphan metabolic ratios from AUC, single point plasma, and urine.
Chen R; Wang H; Shi J; Hu P
Int J Clin Pharmacol Ther; 2016 May; 54(5):330-6. PubMed ID: 26902503
[TBL] [Abstract][Full Text] [Related]
12. The effect of grape seed extract on the pharmacokinetics of dextromethorphan in healthy volunteers.
Goey AK; Meijerman I; Beijnen JH; Schellens JH
Eur J Clin Pharmacol; 2013 Nov; 69(11):1883-90. PubMed ID: 23881421
[TBL] [Abstract][Full Text] [Related]
13. Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates.
Labbé L; Sirois C; Pilote S; Arseneault M; Robitaille NM; Turgeon J; Hamelin BA
Pharmacogenetics; 2000 Jul; 10(5):425-38. PubMed ID: 10898112
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of cytochrome P450 2D6 phenotyping in healthy adult Western Indians.
Gogtay NJ; Mali NB; Iyer K; Kadam PP; Sridharan K; Shrimal D; Thatte UM
Indian J Pharmacol; 2014; 46(3):266-9. PubMed ID: 24987171
[TBL] [Abstract][Full Text] [Related]
15. Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping.
Streetman DS; Ellis RE; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 1999 Nov; 66(5):535-41. PubMed ID: 10579482
[TBL] [Abstract][Full Text] [Related]
16. Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance.
Borges S; Li L; Hamman MA; Jones DR; Hall SD; Gorski JC
Drug Metab Dispos; 2005 Jul; 33(7):1052-5. PubMed ID: 15821042
[TBL] [Abstract][Full Text] [Related]
17. Analysis of pharmacokinetic parameters for assessment of dextromethorphan metabolic phenotypes.
Yeh GC; Tao PL; Ho HO; Lee YJ; Chen JY; Sheu MT
J Biomed Sci; 2003; 10(5):552-64. PubMed ID: 12928596
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphism of CYP2D6 in North Indian subjects.
Lamba V; Lamba JK; Dilawari JB; Kohli KK
Eur J Clin Pharmacol; 1998; 54(9-10):787-91. PubMed ID: 9923585
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of dextromethorphan and its metabolites in horses following a single oral administration.
Corado CR; McKemie DS; Knych HK
Drug Test Anal; 2017 Jun; 9(6):880-887. PubMed ID: 27580591
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition.
Schadel M; Wu D; Otton SV; Kalow W; Sellers EM
J Clin Psychopharmacol; 1995 Aug; 15(4):263-9. PubMed ID: 7593709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]